Decreased activity of the Na+/H+ exchanger by phosphodiesterase 5A inhibition is attributed to an increase in protein phosphatase activity

Hypertension. 2010 Oct;56(4):690-5. doi: 10.1161/HYPERTENSIONAHA.110.151324. Epub 2010 Aug 16.

Abstract

The beneficial effect of phosphodiesterase 5A inhibition in ischemia/reperfusion injury and cardiac hypertrophy is well established. Inhibition of the cardiac Na(+)/H(+) exchanger (NHE-1) exerts beneficial effects on these same conditions, and a possible link between these therapeutic strategies was suggested. Experiments were performed in isolated cat cardiomyocytes to gain insight into the intracellular pathway involved in the reduction of NHE-1 activity by phosphodiesterase 5A inhibition. NHE-1 activity was assessed by the rate of intracellular pH recovery from a sustained acidic load in the absence of bicarbonate. Phosphodiesterase 5A inhibition with sildenafil (1 μmol/L) did not affect basal intracellular pH; yet, it did decrease proton efflux (J(H); in millimoles per liter per minute) after the acidic load (proton efflux: 6.97±0.43 in control versus 3.31±0.58 with sildenafil; P<0.05). The blockade of both protein phosphatase 1 and 2A with 100 nmol/L of okadaic acid reverted the sildenafil effect (proton efflux: 6.77±0.82). In contrast, selective inhibition of protein phosphatase 2A (1 nmol/L of okadaic acid or 100 μmol/L of endothall) did not (3.86±1.0 and 2.61±1.2), suggesting that only protein phosphatase 1 was involved in sildenafil-induced NHE-1 inhibition. Moreover, sildenafil prevented the acidosis-induced increase in NHE-1 phosphorylation without affecting activation of the extracellular signal-regulated kinase 1/2-p90(RSK) pathway. Our results suggest that phosphodiesterase 5A inhibition decreases NHE-1 activity, during intracellular pH recovery after an acidic load, by a protein phosphatase 1-dependent reduction in NHE-1 phosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biological Transport / drug effects
  • Cats
  • Cells, Cultured
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism
  • Dicarboxylic Acids / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Hydrogen-Ion Concentration
  • Immunoblotting
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Okadaic Acid / pharmacology
  • Phosphodiesterase 5 Inhibitors*
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphorylation / drug effects
  • Piperazines / pharmacology*
  • Protein Phosphatase 1 / antagonists & inhibitors
  • Protein Phosphatase 1 / metabolism*
  • Protons
  • Purines / pharmacology
  • Ribosomal Protein S6 Kinases, 90-kDa / metabolism
  • Sildenafil Citrate
  • Sodium-Hydrogen Exchangers / metabolism*
  • Sulfones / pharmacology*

Substances

  • Dicarboxylic Acids
  • Enzyme Inhibitors
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Protons
  • Purines
  • Sodium-Hydrogen Exchangers
  • Sulfones
  • endothall
  • Okadaic Acid
  • Sildenafil Citrate
  • Ribosomal Protein S6 Kinases, 90-kDa
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Protein Phosphatase 1
  • Cyclic Nucleotide Phosphodiesterases, Type 5